Information on the total number of voting rights (denominator)
September 21 2023 - 11:55AM
Information on the total number of voting rights (denominator)
Information on the total number of voting
rights (denominator)
Liege, Belgium, 21
September 2023 –
5:45
pm CEST – Mithra (Euronext
Brussels: MITRA), a company dedicated to Women’s Health, today
announces that, following the first, second and first part of the
third drawdown by the Company under the loan facility concluded by
the Company with certain funds managed by Highbridge Capital
Management, LLC (“Highbridge“) and funds managed by Whitebox
Advisors, LLC (“Whitebox“, and together with Highbridge, the
“Lenders“), another portion of the loans was contributed in kind by
Highbridge against the issuance of new shares.
On 8th August 2022, the Company and the
Lenders entered into a three-year term senior secured convertible
facilities agreement for an amount of up to EUR 100 million,
which can be drawn in three tranches. The first tranche of
EUR 50 million was drawn upon signing of the agreement; the
second tranche of EUR 25 million was drawn on 31st October
2022, and the first part of the third tranche of EUR 12,5 million
was drawn on the 21stJune 2023 following the amendment of the
facilities as announced on 25th May 2023.
Following the first, second and first part of
the third drawdowns, another portion of the loans (including
accrued interest, as relevant, and an option payment amount) was
contributed in kind for an aggregate amount of
EUR 1,157,143.13 through the issuance of 521,339 new shares at
an aggregate issue price of ca. EUR 2.22 per share. Following the
last contribution in kind, the outstanding principal amount of the
loans already drawn is EUR 60,360,161.29.
In accordance with article 15 of the Belgian Act
of 2 May 2007 on the disclosure of major participations in issuers
of which shares are admitted to trading on a regulated market and
regarding miscellaneous provisions, following this capital
increase’s completion Mithra now has 69,108,397 outstanding shares
carrying voting rights (against 68,587,058 outstanding shares
carrying voting rights previously).
Therefore, Mithra publishes the following
updated information:
- Capital: EUR
50,594,032
- Total number of
securities carrying voting rights: 69,108,397 (all ordinary
shares)
- Total number of
voting rights (= denominator): 69,108,397 (all relating to ordinary
shares)
- Number of
outstanding rights to subscribe to securities carrying voting
rights:
- Pursuant to the
share option plan of 5 November 2018: 1,394,900 subscription rights
giving right to 1,394,900 ordinary shares
- Pursuant to the
share option plan of 22 July 2020: 690,000 subscription rights
giving right to 720,571 ordinary shares
- Pursuant to the
share option plan granted to the lending shareholders of 7
September 2020: 300,000 subscription rights giving right to 313,292
ordinary shares
- Pursuant to the
share option plan of 20 November 2020: 390,717 subscription rights
giving rise to 390,717 ordinary shares
For more information, please
contact:
Mithra Pharmaceuticals SADavid Horn SolomonChief
Executive Officerinvestorrelations@mithra.com |
Investor &
media relationsChris MaggosCohesion
Bureauchris.maggos@cohesionbureau.com +41 79 367 6254 |
About Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill Estelle®, Mithra is now
focusing on its second product Donesta®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
ESTELLE®and DONESTA® are registered trademarks
of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive
our press releases by email or follow us on our social media
:Linkedin • Twitter • Facebook |
- 2023-09-20_Mithra_ Denominator_FR_v2
- 2023-09-20_Mithra_ Denominator- EN_v2_ADS
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Nov 2024 to Dec 2024
Mithra Pharmaceuticals (TG:1TM)
Historical Stock Chart
From Dec 2023 to Dec 2024